Diamyd Medical AB (publ) (DMYD-B.ST)
SEK 16.12
(2.54%)
SEK 16.12
(2.54%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -3.58 Million SEK | -15.93% |
| 2023 | -3.08 Million SEK | 21.8% |
| 2022 | -3.94 Million SEK | -75.67% |
| 2021 | -2.24 Million SEK | 45.79% |
| 2020 | -4.14 Million SEK | -3217.6% |
| 2019 | -125 Thousand SEK | 90.96% |
| 2018 | -1.38 Million SEK | -69.07% |
| 2017 | -818 Thousand SEK | -431.17% |
| 2016 | -154 Thousand SEK | 81.62% |
| 2015 | -838 Thousand SEK | -2.32% |
| 2014 | -819 Thousand SEK | -24.85% |
| 2013 | -656 Thousand SEK | -160.85% |
| 2012 | 1.07 Million SEK | -99.62% |
| 2011 | 280.74 Million SEK | 148.44% |
| 2010 | 113 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | -811 Thousand SEK | 94.21% |
| 2024 Q3 | -14 Million SEK | -9.0% |
| 2024 Q2 | -12.84 Million SEK | -1058.61% |
| 2024 Q1 | -1.1 Million SEK | -17.11% |
| 2023 Q1 | -474 Thousand SEK | 22.93% |
| 2023 FY | -3.08 Million SEK | 21.8% |
| 2023 Q4 | -947 Thousand SEK | -43.48% |
| 2023 Q3 | -660 Thousand SEK | 34.52% |
| 2023 Q2 | -1 Million SEK | -112.66% |
| 2022 Q4 | -615 Thousand SEK | 39.23% |
| 2022 FY | -3.94 Million SEK | -75.67% |
| 2022 Q3 | -1.01 Million SEK | 23.28% |
| 2022 Q2 | -1.31 Million SEK | -90.33% |
| 2022 Q1 | -693 Thousand SEK | -91.97% |
| 2021 Q1 | -438 Thousand SEK | 77.97% |
| 2021 Q2 | -935 Thousand SEK | -113.47% |
| 2021 Q3 | -496 Thousand SEK | 46.95% |
| 2021 FY | -2.24 Million SEK | 45.79% |
| 2021 Q4 | -361 Thousand SEK | 27.22% |
| 2020 Q1 | -326 Thousand SEK | -552.0% |
| 2020 Q3 | -1.33 Million SEK | -163.89% |
| 2020 Q4 | -1.98 Million SEK | -49.47% |
| 2020 Q2 | -504 Thousand SEK | -54.6% |
| 2020 FY | -4.14 Million SEK | -3217.6% |
| 2019 Q4 | -50 Thousand SEK | -108.59% |
| 2019 Q1 | -149 Thousand SEK | 57.67% |
| 2019 FY | -125 Thousand SEK | 90.96% |
| 2019 Q2 | -530 Thousand SEK | -255.7% |
| 2019 Q3 | 582 Thousand SEK | 209.81% |
| 2018 Q3 | -723 Thousand SEK | -48.16% |
| 2018 FY | -1.38 Million SEK | -69.07% |
| 2018 Q4 | -352 Thousand SEK | 51.31% |
| 2018 Q2 | -488 Thousand SEK | -321.82% |
| 2018 Q1 | 220 Thousand SEK | 323.08% |
| 2017 FY | -818 Thousand SEK | -431.17% |
| 2017 Q4 | 52 Thousand SEK | 114.25% |
| 2017 Q1 | 267 Thousand SEK | 585.45% |
| 2017 Q2 | -791 Thousand SEK | -396.25% |
| 2017 Q3 | -365 Thousand SEK | 53.86% |
| 2016 FY | -154 Thousand SEK | 81.62% |
| 2016 Q1 | 63 Thousand SEK | 128.0% |
| 2016 Q2 | -64 Thousand SEK | -201.59% |
| 2016 Q3 | -30 Thousand SEK | 53.13% |
| 2016 Q4 | -55 Thousand SEK | -83.33% |
| 2015 Q4 | -225 Thousand SEK | -11350.0% |
| 2015 Q3 | 2000.00 SEK | 100.46% |
| 2015 Q2 | -437 Thousand SEK | -144.13% |
| 2015 Q1 | -179 Thousand SEK | -88.42% |
| 2015 FY | -838 Thousand SEK | -2.32% |
| 2014 Q4 | -95 Thousand SEK | 35.37% |
| 2014 Q2 | -498 Thousand SEK | -530.38% |
| 2014 Q3 | -147 Thousand SEK | 70.48% |
| 2014 Q1 | -79 Thousand SEK | 41.48% |
| 2014 FY | -819 Thousand SEK | -24.85% |
| 2013 Q1 | -190 Thousand SEK | -302.13% |
| 2013 Q4 | -135 Thousand SEK | 17.18% |
| 2013 FY | -656 Thousand SEK | -160.85% |
| 2013 Q3 | -163 Thousand SEK | 2.4% |
| 2013 Q2 | -167 Thousand SEK | 12.11% |
| 2012 Q1 | 54 Thousand SEK | -97.59% |
| 2012 Q4 | 94 Thousand SEK | -72.99% |
| 2012 Q2 | 582 Thousand SEK | 977.78% |
| 2012 Q3 | 348 Thousand SEK | -40.21% |
| 2012 FY | 1.07 Million SEK | -99.62% |
| 2011 Q1 | 144.47 Million SEK | 31.08% |
| 2011 FY | 280.74 Million SEK | 148.44% |
| 2011 Q2 | 114.5 Million SEK | -20.74% |
| 2011 Q3 | 19.52 Million SEK | -82.95% |
| 2011 Q4 | 2.24 Million SEK | -88.51% |
| 2010 Q2 | 164 Thousand SEK | 0.0% |
| 2010 FY | 113 Million SEK | 0.0% |
| 2010 Q3 | 1.33 Million SEK | 712.8% |
| 2010 Q4 | 110.22 Million SEK | 8168.57% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 97.772% |
| Ziccum AB (publ) | -23.28 Million SEK | 84.626% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 101.034% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 108.567% |
| Mendus AB (publ) | 28.48 Million SEK | 112.567% |
| Genovis AB (publ.) | 54 Million SEK | 106.63% |
| Intervacc AB (publ) | -13.79 Million SEK | 74.047% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 264.901% |
| Active Biotech AB (publ) | -1.67 Million SEK | -113.731% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 135.933% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 113.348% |
| Aptahem AB (publ) | 2.63 Million SEK | 236.088% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -4.648% |
| Kancera AB (publ) | -1.96 Million SEK | -82.188% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 4749.351% |
| Fluicell AB (publ) | 1.73 Million SEK | 305.984% |
| Saniona AB (publ) | 11.78 Million SEK | 130.388% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 30.037% |
| Biovica International AB (publ) | 6.87 Million SEK | 152.058% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 84.624% |
| AcouSort AB (publ) | 8.38 Million SEK | 142.675% |
| Xintela AB (publ) | 78 Thousand SEK | 4689.744% |
| Abliva AB (publ) | -35.66 Million SEK | 89.962% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 97.563% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 227.538% |
| OncoZenge AB (publ) | 3000.00 SEK | 119433.333% |
| Amniotics AB (publ) | -1.93 Million SEK | -85.492% |
| 2cureX AB (publ) | -37.48 Million SEK | 90.45% |
| CombiGene AB (publ) | -21.29 Million SEK | 83.185% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -746.336% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.317% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.227% |
| Corline Biomedical AB | 28.38 Million SEK | 112.615% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 97.083% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 89.598% |
| I-Tech AB | 27.56 Million SEK | 112.987% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 105.046% |
| Cyxone AB (publ) | 2.61 Million SEK | 237.112% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 205.201% |
| Biosergen AB | -456 Thousand SEK | -685.088% |
| Cantargia AB (publ) | -3.45 Million SEK | -3.738% |
| NextCell Pharma AB | -43.74 Million SEK | 91.817% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 61.062% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 131.912% |
| Nanologica AB (publ) | -76 Thousand SEK | -4610.526% |
| SynAct Pharma AB | -778 Thousand SEK | -360.154% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -1754.922% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 72.295% |
| Lipum AB (publ) | 53 Thousand SEK | 6854.717% |
| BioInvent International AB (publ) | 71.46 Million SEK | 105.01% |
| Alzinova AB (publ) | 19.87 Million SEK | 118.013% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 109.863% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 344.699% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -23766.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 315.923% |
| Simris Alg AB (publ) | 2 Million SEK | 278.376% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 110.116% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -241.277% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 214.267% |